Table 1 Patient baseline characteristics and treatments
All patients, N = 60 | |
|---|---|
Age at diagnosis, mean (SD), years | 69.3 (9.4) |
White, n (%) | 53 (88.3) |
Female, n (%) | 43 (71.7) |
Previous or current smoking history, n (%) | 21 (35.0) |
New-onset disease, n (%)* | 48 (80.0) |
Clinical manifestations at disease onset | |
Localized headache, n (%) | 47 (78.3) |
Scalp tenderness, n (%) | 26 (43.3) |
Jaw claudication, n (%) | 31 (51.7) |
PMR symptoms, n (%) | 32 (53.3) |
Visual manifestations, n (%) | 22 (36.7) |
Amaurosis fugax, n (%) | 11 (18.3) |
Transient blurry vision, n (%) | 18 (30.0) |
Diplopia, n (%) | 2 (3.3) |
Permanent vision loss, n (%) | 8 (13.3) |
AION, n (%) | 7 (11.7) |
CRAO, n (%) | 1 (1.7) |
Fever, n (%) | 14 (23.3) |
Weight loss, n (%) | 20 (33.3) |
ESR, mean (SD), mm/h | 72.6 (33.6) |
CRP, mean (SD), mg/L | 76.1 (72.7) |
Positive temporal artery biopsy, n/N (%)** | 26/51 (51.0) |
Large-vessel vasculitis, n/N (%)** | 12/28 (42.9) |
Prednisone dose at the time of GCA diagnosis, mean (SD), mg/day | 54.0 (19.0) |
Duration of prednisone use before TCZ initiation, median (IQR), years† | 0.6 (0.2–1.4) |
Use of other immunosuppressants before TCZ initiation, n (%)‡ | 14 (23.3) |
Prednisone dose at TCZ initiation, mean (SD), mg/day | 30.0 (18.3) |
Duration of disease before TCZ initiation , median (IQR), years | 0.6 (0.2–1.6) |
Received TCZ upon disease onset (new-onset disease), n (%)¥ | 15 (25.0) |
Received intravenous TCZ, n (%)§ | 22 (36.7) |
Received subcutaneous TCZ, n (%)§ | 44 (73.3) |
Duration of TCZ treatment, median (IQR), years | 0.5 (0.3–1.4) |